Evolva Holding SA / Key word(s): Miscellaneous
30-Nov-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Reinach, November 30, 2021 – Evolva (SIX:EVE), the Swiss biotech company focused on the research, development and commercialization of ingredients based on nature, announced today that it has entered into a Purchase and Subscription Agreement with VERAISON SICAV Engagement Fund (‘VERAISON’) to purchase 63’751’116 shares in a private placement, raising gross proceeds in the amount of CHF 7.5m. Evolva also announced that Carsten Däweritz, Chief Financial Officer, will depart from the company in May 2022.
Private placement to VERAISON
The shares to be sold to VERAISON will be issued from Evolva’s authorised share capital pursuant to a capital increase expected to occur on or around December 3, 2021, whereby the Company’s share capital will be increased to CHF 51’531’467.65 by an amount of CHF 3’187’555.80, divided into 63’751’116 fully paid-in shares with a nominal value of CHF 0.05 each (the “New Shares”). The pre-emptive rights of existing shareholders with respect to the New Shares are excluded.
Settlement of the transaction is expected to take place on or around December 6, 2021 subject to customary closing conditions, with the New Shares expected to be listed and admitted to trading on SIX Swiss Exchange on the same date.
Following settlement of the private placement, VERAISON’s shareholding in Evolva will represent 6.2% of Evolva’s issued share capital.
Evolva intends to use the gross proceeds from the private placement to finance the ongoing activities to strengthen and further build out its commercial businesses.
Oliver Walker, CEO of Evolva said: ‘After the successful transformation from an R&D to a commercial company, I’m excited and pleased to welcome another long-term oriented investor committed to the next phase of Evolva’s development.’
In order to underline VERAISON’s commitment, Andreas Weigelt, CEO and Senior Partner of VERAISON, will be proposed for election to the Board of Directors of Evolva at the upcoming Annual General Meeting in April 2022.
Departure of Chief Financial Officer
Evolva’s CEO Oliver Walker said: ‘I would like to thank Carsten for his work and efforts during his tenure and I wish him already now the very best in his future endeavours.’
For Evolva multimedia content, please visit: evolva.com/multimedia-library.
About VERAISON Capital Ltd.
End of ad hoc announcement
|Company:||Evolva Holding SA|
|Phone:||+41 61 485 20 00|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1252756|
|End of Announcement||EQS Group News Service|